Osteoarthritis and Bone Disorders News

WASHINGTON — Although even low-dose prednisone significantly increases the risk for fracture in systemic lupus erythematosus, there is no increased risk from intramuscular triamcinolone or intravenous methylprednisolone, said a speaker.

WASHINGTON — Patients treated with a novel neurotrophin-3 inhibitor demonstrated significant reductions in osteoarthritis knee pain across all dosing levels, according to data presented at ACR Convergence 2024.

WASHINGTON — Practices that join the American College of Rheumatology’s RISE registry report “doubled to tripled” rates of improvement in rheumatoid arthritis function and disease activity assessment, according to data.

WASHINGTON — Lorecivivint is superior to placebo for improving pain, function and structure at 12 months and beyond in patients with knee osteoarthritis, according to data presented at ACR Convergence 2024.

Despite a lack of “gold standard” evidence surrounding cannabis use for musculoskeletal pain, rheumatologists must not turn a blind eye to how such products are used by their patients in the real world, according to researchers.

Weight loss from weekly semaglutide injections accompanied significant reductions in pain related to knee osteoarthritis, according to data published in The New England Journal of Medicine.

Patients with knee osteoarthritis in a supervised education and exercise program demonstrated similar clinical outcomes regardless of whether they previously had knee surgery, according to data published in Clinical Rheumatology.

Patients with systemic sclerosis demonstrate lower bone mineral density compared with the general population, with significant differences reported in women aged younger than 45 years, according to data published in Rheumatology.

Current MRI-based definitions of knee osteoarthritis fail to sufficiently pinpoint knees that will later develop radiographic disease visible on X-ray, according to data published in Arthritis & Rheumatology.